Refine by
Clinical Proteomics Identifying And Developing Articles & Analysis: This-Year
1 articles found
CAR-T cell therapy has transformed the treatment landscape for hematological cancers, yet its widespread adoption remains limited by the complexity of ex vivo manufacturing. Patient-specific cell collection, genetic modification, and reinfusion introduce high costs, long timelines, and scalability challenges. To address these barriers, in vivo CAR-T has emerged as a new strategy—engineering ...